PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value
$63.49+0.13 (+0.21%)
Close on Nov 13, 2026Market cap $5.30BP/E –Yield –
PTC Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
PTC Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $438.50M, down 1.9% year over year. For fiscal 2025 it was $455.25M, down 14.8% from the year before. Over ten years it grew 14.1% a year on average. The highest annual figure on record is $666.56M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $455.25M | -14.8% |
| FY2024 | Dec 31, 2024 | $534.48M | -19.8% |
| FY2023 | Dec 31, 2023 | $666.56M | +2.3% |
| FY2022 | Dec 31, 2022 | $651.50M | +20.5% |
| FY2021 | Dec 31, 2021 | $540.68M | +13.2% |
| FY2020 | Dec 31, 2020 | $477.64M | +85.5% |
| FY2019 | Dec 31, 2019 | $257.45M | +49.7% |
| FY2018 | Dec 31, 2018 | $171.98M | +46.4% |
| FY2017 | Dec 31, 2017 | $117.46M | -0.2% |
| FY2016 | Dec 31, 2016 | $117.63M | -3.4% |
| FY2015 | Dec 31, 2015 | $121.82M | +52.6% |
| FY2014 | Dec 31, 2014 | $79.84M | +45.5% |
| FY2013 | Dec 31, 2013 | $54.88M | +18.9% |
| FY2012 | Dec 31, 2012 | $46.14M | -21.4% |
| FY2011 | Dec 31, 2011 | $58.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $105.35M | +5.2% |
| Q2 FY2026 | Jun 30, 2026 | $99.15M | -12.2% |
| Q1 FY2026 | Mar 31, 2026 | $100.87M | -7.4% |
| Q4 FY2025 | Dec 31, 2025 | $133.13M | +6.7% |
| Q3 FY2025 | Sep 30, 2025 | $100.16M | -37.9% |
| Q2 FY2025 | Jun 30, 2025 | $112.99M | -14.5% |
| Q1 FY2025 | Mar 31, 2025 | $108.97M | -6.2% |
| Q4 FY2024 | Dec 31, 2024 | $124.77M | +2.8% |
| Q3 FY2024 | Sep 30, 2024 | $161.41M | -1.7% |
| Q2 FY2024 | Jun 30, 2024 | $132.17M | -28.9% |
| Q1 FY2024 | Mar 31, 2024 | $116.13M | -40.5% |
| Q4 FY2023 | Dec 31, 2023 | $121.35M | -35.7% |
| Q3 FY2023 | Sep 30, 2023 | $164.21M | -0.8% |
| Q2 FY2023 | Jun 30, 2023 | $185.87M | +18.2% |
| Q1 FY2023 | Mar 31, 2023 | $195.12M | +39.3% |
| Q4 FY2022 | Dec 31, 2022 | $188.69M | +25.9% |
| Q3 FY2022 | Sep 30, 2022 | $165.46M | +26.5% |
| Q2 FY2022 | Jun 30, 2022 | $157.26M | +25.3% |
| Q1 FY2022 | Mar 31, 2022 | $140.08M | +4.1% |
| Q4 FY2021 | Dec 31, 2021 | $149.84M | +27.0% |
| Q3 FY2021 | Sep 30, 2021 | $130.85M | +40.7% |
| Q2 FY2021 | Jun 30, 2021 | $125.48M | -28.9% |
| Q1 FY2021 | Mar 31, 2021 | $134.51M | +49.3% |
| Q4 FY2020 | Dec 31, 2020 | $118.01M | +44.2% |
| Q3 FY2020 | Sep 30, 2020 | $93.00M | +47.4% |
| Q2 FY2020 | Jun 30, 2020 | $176.53M | +194.3% |
| Q1 FY2020 | Mar 31, 2020 | $90.11M | +71.4% |
| Q4 FY2019 | Dec 31, 2019 | $81.83M | +52.5% |
| Q3 FY2019 | Sep 30, 2019 | $63.08M | +16.0% |
| Q2 FY2019 | Jun 30, 2019 | $59.98M | +83.9% |
| Q1 FY2019 | Mar 31, 2019 | $52.57M | +67.6% |
| Q4 FY2018 | Dec 31, 2018 | $53.65M | +83.5% |
| Q3 FY2018 | Sep 30, 2018 | $54.37M | +81.1% |
| Q2 FY2018 | Jun 30, 2018 | $32.61M | +5.7% |
| Q1 FY2018 | Mar 31, 2018 | $31.36M | +14.6% |
| Q4 FY2017 | Dec 31, 2017 | $29.23M | +12.4% |
| Q3 FY2017 | Sep 30, 2017 | $30.02M | – |
| Q2 FY2017 | Jun 30, 2017 | $30.84M | – |
| Q1 FY2017 | Mar 31, 2017 | $27.36M | – |
| Q4 FY2016 | Dec 31, 2016 | $26.01M | – |
See a number that looks wrong?